Resona Asset Management Co. Ltd. Acquires Shares of 8,902 Prestige Consumer Healthcare Inc. (NYSE:PBH)

Resona Asset Management Co. Ltd. acquired a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,902 shares of the company's stock, valued at approximately $695,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of PBH. Kestra Investment Management LLC purchased a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth $27,000. CIBC Private Wealth Group LLC grew its holdings in Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after acquiring an additional 152 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $40,000. GAMMA Investing LLC raised its stake in shares of Prestige Consumer Healthcare by 18.9% during the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock valued at $108,000 after acquiring an additional 220 shares during the last quarter. Finally, Huntington National Bank boosted its holdings in shares of Prestige Consumer Healthcare by 133.2% during the fourth quarter. Huntington National Bank now owns 1,481 shares of the company's stock worth $116,000 after purchasing an additional 846 shares during the period. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Stock Performance

NYSE PBH traded up $0.24 on Wednesday, hitting $81.18. 52,522 shares of the company traded hands, compared to its average volume of 353,360. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The business's 50 day moving average price is $84.56 and its 200-day moving average price is $79.97. The company has a market capitalization of $4.02 billion, a price-to-earnings ratio of 19.01, a P/E/G ratio of 2.69 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 52-week low of $62.35 and a 52-week high of $90.04.

Remove Ads

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Mary Beth Fritz sold 1,678 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Royal Bank of Canada boosted their price objective on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a research report on Friday, March 21st. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Oppenheimer raised their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. StockNews.com downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Tuesday, April 8th. Finally, DA Davidson upped their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.